The subject of this publication is the conclusion of discount agreements for the following X-ray contrast media (ATC code according to WHO: V08):

- Lot 1 amidotrizoic acid up to 30 ml,

- Lot 2 amidotrizoic acid more than 30 ml,

- Lot 3 ioxitalamic acid,

- Lot 4 Iohexol,

- Lot 5 Iopamidol,

- Lot 6 Iopromid,

- Lot 7 Ioversol,

- Lot 8 iodixanol,

- Lot 9 Iomeprol up to 350 mg,

- Lot 10 Iomeprol 400 mg,

- Lot 11 iobitridol,

- Lot 12 ethyl esters of iodinated fatty acids,

- Lot 13 barium sulphate with suspending agent,

- Lot 14 gadopentetic acid,

- Lot 15 gadoteric acid,

- Lot 16 Gadoteridol,

- Lot 17 gadobenic acid,

- Lot 18 Gadobutrol,

- lot 19 gadoxetic acid,

- Lot 20 human albumin microspheres,

- Lot 21 phospholipid microspheres,

- Lot 22, sulfur hexafluoride.

For further information see point II.2.4) of the announcement.

The subject of this lot is the conclusion of discount agreements for the active ingredient amidotrizoic acid up to 30 ml (ATC according to WHO: V08AA01) as part of a so-called “open-house model”. In contrast to the start of the contract period, the discount will be granted from 1.4.2021 at the earliest. The contract is concluded as part of the open house procedure. AOK PLUS does not guarantee individual contractual partners any exclusivity. The purchase quantity is unknown when the agreement is concluded and depends in particular on the demand from the insured, the development of the number of insured, the prescription behavior of contract doctors and the dispensing and stocking behavior of public pharmacies. The client does not guarantee any minimum purchase quantities.

Interested contractors can conclude discount agreements during the period from March 12th, 2021 to March 31st, 2022 (with an extension option until March 31st, 2023). The discount agreements and the "open-house procedure" end regardless of the date of the conclusion of the contract at the latest on March 31, 2022 or, after exercising the extension option, on March 31, 2023. Regardless of this, discount agreements and the "open-house procedure" will be terminated before March 31, 2022, such as, as a result of a formal award procedure in accordance with the regulations of Part 4 of the GWB, with one or more contractual partners, exclusive agreements on the under II.1.1) mentioned active substances come into force.

According to the experience of AOK PLUS, exclusive discount agreements usually come into force 8 to twelve months after the publication of the corresponding announcement in the TED supplement to the Official Journal of the European Union. The future contracting parties are requested to inform themselves regularly about these tenders in the TED supplement to the Official Journal of the European Union. Interested contractors can request the participation documents as well as the discount agreement from both contact points named under I.1) by email, stating the lot and active ingredient. The prerequisite for the conclusion of a discount agreement is that the interested contractor has all the participation documents (self-declaration that there are no grounds for exclusion, discount agreement in duplicate, declaration of conformity) fully completed, signed, dated and stamped with the company stamp. A discount agreement is concluded with every contractor who meets the requirements for participation. The participation documents must be submitted in full by post to the contact point named under I.1), for the first time by March 11, 2021 and then by the 15th of each month (deadline for receipt). It depends on the access at the contact point mentioned under I.1). If the 15th of a month falls on a Saturday, Sunday or national public holiday, the next working day takes the place of such a day. If it is received later (after March 11th, 2021 or the 15th of a month), the submitted participation documents will be taken into account on the 15th of the following month.

The discount agreement comes into force on April 1st, 2021 if both parties sign it up to and including March 31, 2021. The AOK health partner portal (www.aok-gesundheitpartner.de) is used to publish the discounted contrast media. AOK PLUS ensures publication on the first of the month after the discount agreement has been signed by AOK PLUS. The first publication will take place on April 1, 2021. If you are unclear or have questions about the discount agreement, please contact the contact point mentioned in I.1) by email only.

AOK PLUS reserves the right to make such questions and the answers to them available to all other interested contractors in anonymised form, provided that these are of general interest within the framework of the procedure.

The subject of this lot is the conclusion of discount agreements for the active ingredient Iomeprol 400 mg (ATC according to WHO: V08AB10) as part of a so-called “open-house model”.

For further information see lot 1 on the active ingredient amidotrizoic acid up to 30 ml, item II.2.4) of the notice.

The subject of this lot is the conclusion of discount agreements for the active ingredient iobitridol (ATC according to WHO: V08AB11) as part of a so-called "open-house model".

For further information see lot 1 on the active ingredient amidotrizoic acid up to 30 ml, item II.2.4) of the notice.

The subject of this lot is the conclusion of discount agreements for the active ingredient ethyl ester of iodinated fatty acids (ATC according to WHO: V08AD01) as part of a so-called "open-house model".

For further information see lot 1 on the active ingredient amidotrizoic acid up to 30 ml, item II.2.4) of the notice.

The subject of this lot is the conclusion of discount agreements for the active ingredient barium sulfate with suspending agent (ATC according to WHO: V08BA01) as part of a so-called "open-house model".

For further information see lot 1 on the active ingredient amidotrizoic acid up to 30 ml, item II.2.4) of the notice.

The subject of this lot is the conclusion of discount agreements for the active ingredient barium sulfate with gadopentetic acid (ATC according to WHO: V08CA01) as part of a so-called “open-house model”.

For further information see lot 1 on the active ingredient amidotrizoic acid up to 30 ml, item II.2.4) of the notice.

The subject of this lot is the conclusion of discount agreements for the active ingredient gadoteric acid (ATC according to WHO: V08CA02) as part of a so-called "open-house model".

For further information see lot 1 on the active ingredient amidotrizoic acid up to 30 ml, item II.2.4) of the notice.

The subject of this lot is the conclusion of discount agreements for the active ingredient gadoteridol (ATC according to WHO: V08CA04) as part of a so-called "open-house model".

For further information see lot 1 on the active ingredient amidotrizoic acid up to 30 ml, item II.2.4) of the notice.

The subject of this lot is the conclusion of discount agreements for the active ingredient gadobenic acid (ATC according to WHO: V08CA08) as part of a so-called “open house model”.

For further information see lot 1 on the active ingredient amidotrizoic acid up to 30 ml, item II.2.4) of the notice.

The subject of this lot is the conclusion of discount agreements for the active ingredient gadobutrol (ATC according to WHO: V08CA09) as part of a so-called "open-house model".

For further information see lot 1 on the active ingredient amidotrizoic acid up to 30 ml, item II.2.4) of the notice.

The subject of this lot is the conclusion of discount agreements for the active ingredient gadoxetic acid (ATC according to WHO: V08CA10) as part of a so-called "open-house model".

For further information see lot 1 on the active ingredient amidotrizoic acid up to 30 ml, item II.2.4) of the notice.

The subject of this lot is the conclusion of discount agreements for the active ingredient amidotrizoic acid more than 30 ml (ATC according to WHO: V08AA01) as part of a so-called “open-house model”.

For further information see lot 1 on the active ingredient amidotrizoic acid up to 30 ml, item II.2.4) of the notice.

The subject of this lot is the conclusion of discount agreements for the active ingredient human albumin microspheres (ATC according to WHO: V08DA01) as part of a so-called "open-house model".

For further information see lot 1 on the active ingredient amidotrizoic acid up to 30 ml, item II.2.4) of the notice.

The subject of this lot is the conclusion of discount agreements for the active ingredient phospholipid microspheres (ATC according to WHO: V08DA04) as part of a so-called "open-house model".

For further information see lot 1 on the active ingredient amidotrizoic acid up to 30 ml, item II.2.4) of the notice.

The subject of this lot is the conclusion of discount agreements for the active ingredient sulfur hexafluoride (ATC according to WHO: V08DA05) as part of a so-called "open-house model".

For further information see lot 1 on the active ingredient amidotrizoic acid up to 30 ml, item II.2.4) of the notice.

The subject of this lot is the conclusion of discount agreements for the active ingredient ioxitalamic acid (ATC according to WHO: V08AA05) as part of a so-called "open-house model".

For further information see lot 1 on the active ingredient amidotrizoic acid up to 30 ml, item II.2.4) of the notice.

The subject of this lot is the conclusion of discount agreements for the active substance iohexol (ATC according to WHO: V08AB02) as part of a so-called "open-house model".

For further information see lot 1 on the active ingredient amidotrizoic acid up to 30 ml, item II.2.4) of the notice.

The subject of this lot is the conclusion of discount agreements for the active ingredient iopamidol (ATC according to WHO: V08AB04) as part of a so-called "open-house model".

For further information see lot 1 on the active ingredient amidotrizoic acid up to 30 ml, item II.2.4) of the notice.

The subject of this lot is the conclusion of discount agreements for the active ingredient iopromide (ATC according to WHO: V08AB05) as part of a so-called "open-house model".

For further information see lot 1 on the active ingredient amidotrizoic acid up to 30 ml, item II.2.4) of the notice.

The subject of this lot is the conclusion of discount agreements for the active ingredient Ioversol (ATC according to WHO: V08AB07) as part of a so-called "open house model".

For further information see lot 1 on the active ingredient amidotrizoic acid up to 30 ml, item II.2.4) of the notice.

The subject of this lot is the conclusion of discount agreements for the active ingredient iodixanol (ATC according to WHO: V08AB09) as part of a so-called "open-house model".

For further information see lot 1 on the active ingredient amidotrizoic acid up to 30 ml, item II.2.4) of the notice.

The subject of this lot is the conclusion of discount agreements for the active ingredient Iomeprol up to 350 mg (ATC according to WHO: V08AB10) as part of a so-called "open-house model".

For further information see lot 1 on the active ingredient amidotrizoic acid up to 30 ml, item II.2.4) of the notice.